New Drug Application (NDA) submission for topical roflumilast cream as a potential treatment for plaque psoriasis anticipated in the second half of 2021
Positive Phase 3 results for topical roflumilast cream in plaque psoriasis announced in February
Advancing topical roflumilast foam into Phase 3 development for the treatment of scalp psoriasis with a single pivotal trial
Progressing topical roflumilast foam into Phase 3 development in seborrheic dermatitis with a single pivotal trial
Pivotal Phase 3 trials of topical roflumilast cream in atopic dermatitis initiated in January
Phase 1/2b study of ARQ-252 in chronic hand eczema did not meet its primary endpoint
Strong financial position with over $440 million in cash, cash equivalents and marketable securities providing cash runway well into 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.